Trial reportJournal of substance abuse treatment2013
Retention in methadone and buprenorphine treatment among African Americans.
Trial report in Journal of substance abuse treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Guideline
- Retention in medication-assisted treatment for opiate dependence: A systematic review.Journal of addictive diseases · 2016Pooled it
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.The Cochrane database of systematic reviews · 2014Pooled it
- Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial.Drug and alcohol dependence · 2024Trial
- Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge.The American journal on addictions · 2017Trial
- Leaving buprenorphine treatment: patients' reasons for cessation of care.Journal of substance abuse treatment · 2014Trial
- Harm reduction engagement and ongoing opioid use among adults receiving methadone or buprenorphine in Philadelphia.Harm reduction journal · 2026Article
- Associations between COVID impact domains and time to buprenorphine treatment disengagement.The American journal of drug and alcohol abuse · 2025Article
- Relationship between patient activation and utilisation of health care and harm reduction services among people who inject drugs in Baltimore, Maryland.Drug and alcohol review · 2024Article
- The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.Addiction (Abingdon, England) · 2023Article
- Article
- Exploring the provider and organization level barriers to medication for opioid use disorder treatment for Black Americans: A study protocol.Public health in practice (Oxford, England) · 2022Article
- Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.Journal of racial and ethnic health disparities · 2022Article
- Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment.Substance abuse : research and treatment · 2022Article
- The Feasibility and Utility of Harnessing Digital Health to Understand Clinical Trajectories in Medication Treatment for Opioid Use Disorder: D-TECT Study Design and Methodological Considerations.Frontiers in psychiatry · 2022Article
- A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health Data.European addiction research · 2021Article
- The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.Addiction (Abingdon, England) · 2021Observational
- Opioid-related overdose deaths among African Americans: Implications for research, practice and policy.Drug and alcohol review · 2020Article
- Review
- A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.Harm reduction journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Methadone has been the most commonly used pharmacotherapy for the treatment of opioid dependence in U.S. public sector treatment, but availability of buprenorphine as an alternative medication continues to increase. Drawing data from two community-based clinical trials that were conducted nearly contemporaneously, this study examined retention in methadone versus buprenorphine treatment over 6 months among urban African Americans receiving treatment in one of four publicly-funded programs (N=478; 178 methadone; 300 buprenorphine). Adjusting for confounds related to medication selection, survival analysis revealed that buprenorphine patients are at substantially higher risk of dropout compared to methadone patients (HR=2.43; p<.001). Buprenorphine's retention disadvantage appears to be concentrated in the earlier phases of treatment (approximately the first 50 days), after which risk of subsequent dropout becomes similar for the two medications. These findings confirm a retention disparity between methadone and buprenorphine in this population, and suggest potential avenues for future research to enhance retention in buprenorphine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.